Search results for "CoV"

showing 10 items of 9749 documents

Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study

2022

Breast milk is a vehicle to transfer protective antibodies from the lactating mother to the neonate. After SARS-CoV-2 infection, virus-specific IgA and IgG have been identified in breast milk, however, there are limited data on the impact of different COVID-19 vaccine types in lactating women. This study is aimed to evaluate the time course of induction of SARS-CoV-2-specific IgA and IgG in breast milk after vaccination.

AdultLongitudinal studyBreast milkCOVID-19 VaccinesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BreastfeedingimmunoglobulinsImmunoglobulinsBreast milkAntibodies ViralVacunesAntibodiesVirusPersistence (computer science)ChAdOx1 nCoV-19GeneticsHumansLactationMedicineantibodiesLongitudinal Studiesskin and connective tissue diseasesMolecular BiologyBNT162 VaccineGenetics (clinical)Milk Humanbiologybusiness.industrySARS-CoV-2VaccinationInfant Newbornfood and beveragesInfantCOVID-19vaccinesImmunoglobulin AVaccinationLlet maternaImmunoglobulin GImmunologybiology.proteinMolecular Medicinebreast milkFemaleAntibodybusiness
researchProduct

Influence of the structural components of artificial turf systems on impact attenuation in amateur football players

2019

AbstractThe purpose of this research was to evaluate the influence of the structural components of different 3rd generation artificial turf football field systems on the biomechanical response of impact attenuation in amateur football players. A total of 12 amateur football players (24.3 ± 3.7 years, 73.5 ± 5.5 kg, 178.3 ± 4.1 cm and 13.7 ± 4.3 years of sport experience) were evaluated on three third generation artificial turf systems (ATS) with different structural components. ATS were composed of asphalt sub-base and 45 mm of fibre height with (ATS1) and without (ATS2) elastic layer or compacted granular sub-base, 60 mm of fibre height without elastic layer (ATS3). Two triaxial accelerome…

AdultMale0301 basic medicineAccelerationPoison controlSTRIDElcsh:MedicineFútbolArticleLower energyRunningYoung Adult03 medical and health sciences0302 clinical medicineFloors and FloorcoveringsSoccerArtificial turfHumanslcsh:ScienceMathematicsOrthodonticsEsportsFootball playersMultidisciplinaryAttenuationlcsh:RDeporteBone quality and biomechanicsBiomechanical Phenomena030104 developmental biologyRisk factorsAthletesFootball fieldSuperficies deportivas sintéticaslcsh:QEducació físicaAmateur030217 neurology & neurosurgeryInstalación deportiva
researchProduct

Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306)

2016

We explored the association of early tumor shrinkage (ETS) and non-ETS with efficacy of first-line and consecutive second-line treatment in patients with KRAS wild-type metastatic colorectal cancer treated in FIRE-3. Assessment of tumor shrinkage was based on the sum of longest diameters of target lesions, evaluated after 6 weeks of treatment. Shrinkage was classified as ETS (shrinkage by ≥ 20%), mETS (shrinkage by 0 to20%), mPD (minor progression0 to20%) and PD (progression ≥20%). Overall survival (OS) was 33.2 (95% CI 28.0-38.4) months in ETS patients, while non-ETS was associated with less favorable outcome (mETS 24.0 (95% CI 21.2-26.9) months, mPD 19.0 (95% CI 13.0-25.0) months, PD 12.8…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancerLeucovorinCetuximabKaplan-Meier Estimatemedicine.disease_causeGastroenterologyDisease-Free SurvivalProto-Oncogene Proteins p21(ras)03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedShrinkageCetuximabbusiness.industryRemission InductionTumor shrinkageMiddle Agedmedicine.diseaseBevacizumabTreatment Outcome030104 developmental biologyOncologyFluorouracil030220 oncology & carcinogenesisFOLFIRICamptothecinFemaleFluorouracilKRASColorectal Neoplasmsbusinessmedicine.drugInternational Journal of Cancer
researchProduct

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic aden…

2020

Abstract Background Chemotherapy is effective in metastatic pancreatic adenocarcinoma (mPA), but new approaches are still needed to improve patients' survival and quality of life. We have previously published good efficacy and tolerability results on a sequential treatment strategy of gemcitabine followed by an intensified FOLFIRI (5FU+irinotecan) regimen. In the present study, we evaluated the same sequence but replaced gemcitabine by the new gemcitabine + nab-paclitaxel standard first-line combination. Patients and methods We randomised chemotherapy-naive patients with proven mPA, bilirubin levels ≤1.5 upper limit of normal values and performance status 0–2 to alternately receive gemcitab…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyPaclitaxelPopulationLeucovorinPhases of clinical researchAdenocarcinomaNeutropeniaIrinotecanDeoxycytidineGastroenterology03 medical and health sciences0302 clinical medicineAlbuminsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasiseducationAgededucation.field_of_studyDrug Substitutionbusiness.industryMiddle Agedmedicine.diseaseGemcitabineNeoadjuvant TherapyProgression-Free SurvivalGemcitabinePancreatic NeoplasmsIrinotecanTreatment Outcome030104 developmental biologyOncologyTolerability030220 oncology & carcinogenesisDisease ProgressionFOLFIRICamptothecinFemaleFluorouracilFrancebusinessFebrile neutropeniamedicine.drugEuropean Journal of Cancer
researchProduct

Ultra-Performance Liquid Chromatography-Ion Mobility Separation-Quadruple Time-of-Flight MS (UHPLC-IMS-QTOF MS) Metabolomics for Short-Term Biomarker…

2020

A major problem with dietary assessments is their subjective nature. Untargeted metabolomics and new technologies can shed light on this issue and provide a more complete picture of dietary intake by measuring the profile of metabolites in biological samples. Oranges are one of the most consumed fruits in the world, and therefore one of the most studied for their properties. The aim of this work was the application of untargeted metabolomics approach with the novel combination of ion mobility separation coupled to high resolution mass spectrometry (IMS-HRMS) and study the advantages that this technique can bring to the area of dietary biomarker discovery, with the specific case of biomarker…

AdultMale0301 basic medicineCitruslcsh:TX341-641Orange (colour)Diet Surveys01 natural sciencesorange intakeArticleMass SpectrometryEating03 medical and health sciencesMetabolomicsion mobilityIon Mobility SpectrometryHumansBiomarker discoveryChromatography High Pressure LiquidCross-Over Studies030109 nutrition & dieteticsNutrition and DieteticsChromatographyPlasma samplesChemistryDietary intake010401 analytical chemistryfood and beveragesbiomarkersCrossover studyIntervention studiesmetabolomicsHealthy Volunteers0104 chemical sciencesDietary biomarkersFemalelcsh:Nutrition. Foods and food supplyFood Science
researchProduct

B and T cell immune responses elicited by the Comirnaty® COVID-19 vaccine in nursing home residents

2021

Objectives The immunogenicity of the Comirnaty® COVID-19 vaccine is understudied in elderly people with comorbidities. SARS-CoV-2-S-targeted antibody and T cell responses following full vaccination were assessed in nursing home residents. Methods Sixty nursing home residents (44 female; age, 53-100 years), of whom 10 had previously been diagnosed of COVID-19, and 18 healthy controls (15 female; age, 27-54 years) were recruited. Pre- and post-vaccination blood specimens were available for quantitation of total antibodies binding SARS-CoV-2 S protein and enumeration of SARS-CoV-2-S-reactive IFN-γ CD4+ and CD8+ T cells by flow cytometry. Results The seroconversion rate in presumably SARS-CoV-2…

AdultMale0301 basic medicineMicrobiology (medical)COVID-19 VaccinesSARS-CoV-2-S antibodiesT-LymphocytesT cell030106 microbiologyNursing home residentsAntibodies ViralFlow cytometryInterferon-gamma03 medical and health sciences0302 clinical medicineImmune systemComirnaty®COVID-19 vaccinemedicineHumans030212 general & internal medicineSeroconversionAgedAged 80 and overB-Lymphocytesbiologymedicine.diagnostic_testbusiness.industrySARS-CoV-2ImmunogenicityImmunityCOVID-19General MedicineMiddle AgedNursing HomesVaccinationInfectious Diseasesmedicine.anatomical_structureSARS-CoV-2-S T cellsSpike Glycoprotein CoronavirusImmunologybiology.proteinFemaleOriginal ArticleAntibodybusinessCD8Clinical Microbiology and Infection
researchProduct

A Phase I–II Study on the Toxicity and Therapeutic Efficacy of 5-Fluorouracil in Combination with Leucovorin and Cisplatinum in Patients with Advance…

1990

5-Fluorouracil (5-FU) has been the treatment of choice for colorectal carcinoma with an overall response rate of about 20%. Recent studies have shown that folate (LV) can increase 5-FU therapeutic efficacy, achieving about a 40% response rate without a clear impact on survival. Cisplatinum (CDDP) is usually inactive in colorectal carcinoma, but the association with 5-FU results in a synergistic antineoplastic effect. A phase I-II study was done to assess the maximally tolerated dose (MTD) of CDDP in association with 5-FU + LV. The MTD for CDDP was 20 mg/m2/wk in association with 5-FU 400-500 mg/m2/wk and LV 500 mg/m2/wk. WHO criteria were used for evaluation of both toxicity and response. I…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyColorectal cancerNausea030106 microbiologyLeucovorinGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicinePharmacology (medical)In patientAgedPharmacologyCisplatinClinical Trials as Topicbusiness.industryMiddle Agedmedicine.diseaseDiarrheaInfectious DiseasesOncologyFluorouracil030220 oncology & carcinogenesisToxicityVomitingDrug EvaluationFemaleFluorouracilCisplatinmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugJournal of Chemotherapy
researchProduct

Biomarker discovery study of inflammatory proteins for colorectal cancer early detection demonstrated importance of screening setting validation

2018

Abstract Objectives Most studies identifying inflammatory markers for early detection of colorectal cancer (CRC) were conducted using clinically manifest cases. We aimed to identify circulating inflammatory biomarkers for early detection of CRC and validate them in both a clinical setting and a true screening setting. Study Design and Setting A total of 92 inflammatory proteins were quantified in baseline plasma samples from individuals clinically diagnosed with CRC and neoplasm-free controls matched on age and sex (training set). A multimarker panel was selected and evaluated in samples from another clinical setting (validation set C) and a screening setting (validation set S). Results In …

AdultMale0301 basic medicineOncologymedicine.medical_specialtyEpidemiologyColorectal cancerEarly detectionSensitivity and Specificity03 medical and health sciences0302 clinical medicineInternal medicineBiomarkers TumorHumansMedicineProspective StudiesBiomarker discoveryEarly Detection of CancerAgedAged 80 and overTraining setColorectal cancer early detectionbusiness.industryMiddle AgedCancer Early Detectionmedicine.diseaseInflammatory biomarkers030104 developmental biologyArea Under Curve030220 oncology & carcinogenesisBiomarker (medicine)FemaleColorectal NeoplasmsbusinessAlgorithmsJournal of Clinical Epidemiology
researchProduct

Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial

2018

Background:Gastric cancer is common malignancy and exhibits a poor prognosis. At the time of diagnosis, the majority of patients present with metastatic disease which precludes curative treatment. Non-invasive biomarkers which discriminate early from advanced stages or predict the response to treatment are urgently required. This study explored the cytokeratin-18 fragment M30 and full-length cytokeratin-18 M65 in predicting treatment response and survival in a randomized, placebo-controlled trial of advanced gastric cancer.Methods:Patients enrolled in the SUN-CASE study received sunitinib or placebo as an adjunct to standard therapy with leucovorin (Ca-folinate), 5-fluorouracil, and irinote…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyIndolesmedicine.medical_treatmentLeucovorinAntineoplastic AgentsPlaceboDisease-Free SurvivalMetastasislaw.inventionPlacebos03 medical and health sciences0302 clinical medicineRandomized controlled trialStomach NeoplasmslawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorSunitinibHumansMedicinePyrrolesProgression-free survivalRC254-282AgedAged 80 and overChemotherapyKeratin-18business.industrySunitinibCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineMiddle Agedmedicine.diseasePeptide FragmentsIrinotecan030104 developmental biology030220 oncology & carcinogenesisCamptothecinFemaleFluorouracilbusinessmedicine.drugTumor Biology
researchProduct

A Phase I Study of Cisplatinum plus 5-Fluorouracil in Modulation with Citrovorum Factor in Metastatic Colorectal Carcinoma

1991

A phase I study of 5-fluorouracil 600 mg/m2/week and folinic acid 500 mg/m2/week on day 1 and cisplatin administered weekly on day 2 was carried out on 30 patients with metastatic colorectal carcinoma of which 20 patients were pretreated with 5-fluorouracil. The first group of patients received cisplatin at the dose of 5 mg/m2/week. Cisplatin was then escalated to 10, 15, 20, 25, 30, and 35 mg/m2/week for subsequent groups of patients. Gastrointestinal side-effects were the dose-limiting toxicity. A therapy related death was seen at the dose of 35 mg/m2/week of cisplatin. The maximally tolerated dose of cisplatin in combination with 5-fluorouracil and citrovorum factor is 20 mg/m2/week. The…

AdultMale0301 basic medicinemedicine.medical_specialtyColorectal cancer030106 microbiologyLeucovorinPhases of clinical researchRectumGastroenterologyMetastasis03 medical and health sciencesFolinic acid0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Neoplasm MetastasisAgedPharmacologyCisplatinbusiness.industryCarcinomaRemission InductionMiddle Agedmedicine.diseaseSurgeryInfectious Diseasesmedicine.anatomical_structureOncologyFluorouracil030220 oncology & carcinogenesisToxicityDrug EvaluationFemaleFluorouracilCisplatinColorectal Neoplasmsbusinessmedicine.drugJournal of Chemotherapy
researchProduct